In-frame fusion of two transcription factor genes, TEL (ETV6) on chromosome 12p and AML1 (RUNX1) on chromosome 21q, is thought to be an initiating event in ∼25% of childhood acute lymphoblastic leukemias (ALL). TEL-AML1 fusion leads to the expression of a chimeric oncoprotein which interferes with the function of the normal AML1 protein, leading to arrested B cell development, and enhanced B cell progenitor self-renewal. In vitro studies showed that a TEL-AML1 junctional peptide induced HLA-DP-restricted CD4+ T cell responses. Although expression of TEL-AML1 by pro-leukaemic cells makes it an attractive immunotherapeutic target, information on the number, position, and population distribution of HLA-DR-restricted CD4+ T cell epitopes in TEL-AML1 has not been published. Here, we used the artificial neural network algorithm, NetMHCIIpan (Nielsen et al, PLoS Computational Biology, 2008, 4(7), e1000107) to predict DR-restricted T cell epitopes in TEL-AML1. The 797 residue fusion oncoprotein was screened using NetMHCIIpan to identify 9-mer DR-binding core peptides. 15-mer peptide sequences were submitted in FASTA format to the NetMHCIIpan server (http://www.cbs.dtu.dk/services/NetMHCIIpan/) to facilitate discovery of peptides with strong binding affinity (IC50:<50 nM). Consensus T cell epitopes predicted to provide maximum coverage across common DR alleles in 4 ethnic groups were identified. Overlapping 15-mer junctional sequences were screened to identify a 9-mer DR-binding core sequence, and P1,4,6, and 9 substituted with all 20 amino acids to identify junctional sequences with enhanced (heteroclitic) binding affinity. NetMHCIIpan predicted 45 TEL-AML1 epitopes binding to 22 common DR alleles in 4 ethnic groups. Fourteen epitopes are in TEL and 31 in AML1, with 5 epitopes binding to 5-8 DR alleles, and 1 binding to 10 alleles. Three TEL peptides achieve the greatest population coverage across all ethnic groups, one peptide (266IQLMPSPIM274) giving maximal coverage (25.5-50.1%). Weak DRB1*0101-restricted binding of a junctional peptide (332IGRIA/ECIL340) (415 nM) was strongly increased (52 nM) by substituting serine for glutamic acid at the P6 position. A junctional peptide (332FGRMA/SCIV343) with substitutions at P1, P4 and P9 had enhanced DRB1*0101 affinity (13 nM). These predictions suggest wide population coverage of a small number of strongly binding TEL-AML1 epitopes. The binding affinity of a junctional peptide is enhanced by substituting key anchor residues. Functional studies are now required to distinguish CD4+ T cell-activating TEL-AML1 epitopes inducing anti-leukemic, autoimmune, and regulatory T cell responses.
Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2395.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.